Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Jul;80(10):1644-7.
doi: 10.1038/sj.bjc.6690575.

Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation

Affiliations
Free PMC article

Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation

U Menon et al. Br J Cancer. 1999 Jul.
Free PMC article

Abstract

We have previously shown that, in asymptomatic post-menopausal women, serum CA125 elevation is associated with a 36-fold increase in risk of ovarian cancer. This study was undertaken to assess the value of pelvic ultrasound for further stratification of ovarian cancer risk. Of 22,000 post-menopausal women, aged > or = 45 participating in an Ovarian Cancer Screening Trial, 741 with a CA125 > or = 30 U ml(-1) underwent pelvic ultrasonography. Twenty index cancers (primary invasive epithelial carcinomas of the ovary and fallopian tube) were diagnosed amongst these 741 women during a median follow-up of 6.8 years. Ultrasound results separated the women with CA125 elevation into two groups. Those with normal ovarian morphology had a cumulative risk (CR) of index cancer of 0.15% (95% confidence interval (CI) 0.02-1.12) which is similar to that of the entire population of 22,000 women (0.22%, 95% CI 0.18-0.30). In contrast, women with abnormal ovarian morphology had a CR of 24% (15-37) and a significantly increased relative risk (RR) of 327 (156-683). Ultrasound can effectively separate post-menopausal women with raised CA125 levels into those with normal scan findings who are not at increased risk of index cancer and those with abnormal findings who are at substantially increased risk of index cancer.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lancet. 1988 Feb 6;1(8580):268-71 - PubMed
    1. BMJ. 1989 Dec 2;299(6712):1363-7 - PubMed
    1. Br J Obstet Gynaecol. 1990 Oct;97(10):922-9 - PubMed
    1. BMJ. 1993 Apr 17;306(6884):1030-4 - PubMed
    1. BMJ. 1996 Nov 30;313(7069):1355-8 - PubMed

Publication types